Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder

Neurology

Volumn 86, Issue 19, 2016, Pages 1772-1779

  Hyun, Jae Won ^a   Jeong, In Hye ^a   Joung, Aeran ^a   Kim, Su Hyun ^a   Kim, Ho Jin ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; IMMUNOGLOBULIN G;

ADULT; AREA POSTREMA; ARTICLE; CELL ASSAY; CLINICAL FEATURE; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE DURATION; ENCEPHALE ISOLE; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; EYE DISEASE ASSESSMENT; FEMALE; HUMAN; IMMUNOASSAY; INTERNATIONAL PANEL FOR NEUROMYELITIS OPTICA DIAGNOSIS CRITERIA; MAJOR CLINICAL STUDY; MALE; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE ASSESSMENT; NEUROMYELITIS OPTICA SPECTRUM DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPTIC NEURITIS; PRIORITY JOURNAL; SEROCONVERSION; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; FOLLOW UP; IMMUNOLOGY; METABOLISM; NEUROMYELITIS OPTICA; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; AQUAPORIN 4; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; NEUROMYELITIS OPTICA; RETROSPECTIVE STUDIES;

EID: 84978395255     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002655     Document Type: Article

References (37)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202:473-477.
3. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66:617-629.
4. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuro-myelitis optica. Lancet Neurol 2012;11:535-544.
5. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromye-litis optica. Lancet Neurol 2007;6:805-815.
6. Nagaishi A, Takagi M, Umemura A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry 2011;82:1360-1364.
7. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Clinical spec trum of CNS aquaporin-4 autoimmunity. Neurology 2012;78:1179-1185.
8. Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013;80:2210-2216.
9. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromye-litis optica. Neurology 2006;66:1485-1489.
10. Collongues N, Marignier R, Zephir H, et al. High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler 2011;17:720-724.
11. Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromye-litis optica with myelitis. Neurology 2009;73:1628-1637.
12. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65:1479-1482.
13. Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005; 11:617-621.
14. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-396.
15. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-968.
16. Nakamura M, Misu T, Fujihara K, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 2009;15:695-700.
17. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis op-tica spectrum disorders. Neurology 2009;72:712-717.
18. Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010; 16:1229-1236.
19. Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 2014;20:843-847.
20. Kim W, Kim SH, Lee SH, Li XF, Kim HJ. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler 2011;17:1107-1112.
21. Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013;80:1330-1337.
22. Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84:1165-1173.
23. Kim SH, Huh SY, Hyun JW, et al. A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder. PLoS One 2014;9:e108320.
24. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis opti-ca spectrum disorders. Neurology 2015;85:177-189.
25. Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010;291:52-56.
26. Kim W, Lee JE, Li XF, et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosor-bent assay using purified recombinant human aquaporin-4. Multi Scler 2012;18:578-586.
27. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010;298:158-162.
28. Hyun JW, Kim SH, Huh SY, et al. Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. Mult Scler 2015;21:710-717.
29. Zandoná ME, Kim SH, Hyun JW, et al. The onset location of neuromyelitis optica spectrum disorder predicts the location of subsequent relapses. Mult Scler 2014;20:1908-1911.
30. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6:383-392.
31. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671.
32. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuro-myelitis optica. Neurology 2013;81:1197-1204.
33. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 2013;80: 2194-2200.
34. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuro-myelitis optica: a multicenter study of 175 patients. J Neu-roinflammation 2012;9:14.
35. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-1277.
36. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-481.
37. Pittock SJ, Lennon VA, Bakshi N, et al. Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol 2014;71:1433-1436.